Fig. 9

Elevated JMJD6 acetylation predicts a favorable survival in NSCLC patients. (A) The acetylation level of JMJD6 was detected by immunohistochemistry in 68 cases of lung cancer and precancerous lesions. Representative images are shown on the right and statistical data analysis on the left. The scale bars represent 100 μm. (B) Sixty-eight lung cancer patients were clinically selected and divided into two groups, low (0–7) and high (8–12), according to the expression level of JMJD6-acK375. Then the expression of JMJD6-acK375 in lung cancer was tested whether it was related to gender, age, differentiation degree, tumour size and TNM stage, respectively. (C) The expression of JMJD6-acK375 was examined in 68 lung cancer tissues with TNM stage I-II and stage III-IV. (D) JMJD6-acK375 expression was detected in 68 cases of tumor tissues with tumor size greater than or equal to 5 cm and less than 5 cm. (E) Kaplan-Meier analysis of JMJD6 hyperacetylation level, log-rank test, P = 0.022. (F) The working model elucidates the molecular mechanism through which JMJD6 influences the expression of its downstream target METTL14 both pre- and post-acetylation, consequently impacting the expression of the ferroptosis-related protein SLC3A2. In this process, we demonstrated that acetylated JMJD6 enhances METTL14 expression by elevating H4R3me2a levels, whereas METTL14 overexpression suppresses SLC3A2 expression and impedes the progression of lung cancer cells by facilitating ferroptosis